The findings highlight the need for research on potential benefits and harms of long-term use of opioids and efforts to restrict long-term use to patients for whom the benefits outweigh the risks.
| INTRODUCTION
Over the past 2 decades, prescription of opioids has increased dramatically in the USA and less so in other countries. [1] [2] [3] [4] [5] [6] [7] [8] In a study based on a national surveys of office-based physicians, the visits that included an opioid prescription increased from 0.65% in 1995-1998 to 2.63% in [2007] [2008] [2009] [2010] . 5 This increase has been associated with concurrent increases in misuse of these medications, increased morbidity, and higher rates of mortality due to opioid overdose. 3, [9] [10] [11] [12] [13] [14] [15] There are indications that the growing trend in overall prescription and use of opioid medications has been associated with an even faster growing trend in long-term use of these medications, at least in the first half of the last decade. 3, 9, 16 While there is little research on potential benefits and harms of long-term use of opioids, available data suggest that long-term use of these medications may be associated with opioid misuse. 10, [17] [18] [19] [20] [21] These concerns are reflected in practice guidelines for management of pain published in recent years. [22] [23] [24] The impact of these guidelines on clinician practice patterns is not known. In this context, the present study sought to examine recent trends in the use and, especially, long-term use of prescription opioids in the USA.
More specifically, the study used data from 16 years of the National Health and Nutritional Examination Survey (NHANES) for years 1999 to 2014 to examine trends in use of prescription opioids as well as long-term use of opioids. In addition, associations of longterm use with indicators of elevated risk of adverse effects from opioid treatment were examined, including presence of painful conditions, severe medical conditions, concomitant use of benzodiazepines, and history of heroin and alcohol misuse. [25] [26] [27] [28] [29] These data would have implications for future policies and initiatives aimed at curbing the current epidemic of prescription opioid use. The data would also be useful in identifying population groups who would benefit most from efforts to limit the long-term use of these medications.
2 | METHODS
| Sample
NHANES is a nationally representative survey of the US general population conducted by the National Center for Health Statistics.
30
This study has not been previously presented or reported and is not sponsored by a funding agency. The author declares no conflict of interest.
Starting in 1999, the NHANES has been conducted biannually. We used data from 8 contiguous surveys (1999-2000 through 2013-2014) . Each survey examined a sample of more than 5000 adults located in counties across the country. Computerized interviews were conducted in the participants' homes (response rate = 71.0%-84.0%). A total of 47 356 adults participated in interviews across the 8 surveys.
| Assessments
Prescription opioid medications were identified from the prescription medication interviews which asked the participants to identify medications used in the past 30 days for which a prescription was needed. The following medications or ingredients were categorized as opioid medications for this study: hydrocodone, oxycodone, propoxyphene, codeine, tramadol, opium, morphine, fentanyl, hydromorphone, meperidine, pentazocine, oxymorphone, and tapentadol. Methadone and buprenorphine were not included in the analyses as these medications are often used for treatment of opioid use disorder.
The length of time the participant had been taking each medication was also recorded. For participants taking more than 1 opioid medication, the duration of medication use was defined by the duration of the longest used medication. Length of use was categorized into short-term (<90 days) and long-term (≥90 days) based on studies that have examined adverse health outcomes associated with this pattern of opioid use. 3, 27 In addition, in sensitivity analyses, an alternative definition of duration of ≥30 days for long-term use was also examined.
The interviewers were instructed to inspect the medication packages to confirm participant reports. Medication packages were inspected and confirmed for 84.3% of all medications reported. To assess the impact of this ascertainment method, in sensitivity analyses, the analyses for temporal trends were repeated by restricting the medications to those verified by inspection of medication package.
Beginning with NHANES 2013-2014, participants were asked about the main "reason" for using each medication. A list of possible indicated and off-label reasons for use was pre-assigned to each selected drug and displayed on the computer. The interviewer was instructed to select up to 3 reasons which best matched the main reason described by the participant. For this study, these reasons were combined into 9 broad categories: back pain; other arthritis and joint pain; injury-related pain; muscle and soft-tissue pain; neuropathic pain;
head, face and neck pain; upper respiratory infections; other specific conditions; and unspecific pain.
Benzodiazepine medications were also identified in the prescription medication module using the method described above. ties (eg, pushing or pulling large objects, walking for a quarter of a mile, house chores). Participants who reported having "some difficulty" or "much difficulty" or reported that they were unable to do any of these activities were then asked to choose from a list up to 5 conditions or health problems that had caused the difficulty.
Participants were rated as having disability due to a painful condition if they chose "arthritis/rheumatism", "back or neck problem", or "fractures, bone/joint injury" as a health condition that had caused their disability.
Chronic health conditions and health status were ascertained based on self-reports of arthritis, diabetes, thyroid problems, hypertension, hypercholesterolemia, angina, coronary arterial disease, heart attack, stroke, asthma, bronchitis, emphysema, hepatic disease, and cancer. Separate questions were asked for each condition, and the total number of chronic physical health conditions was computed based on the responses to these questions. In addition, participants were asked to rate their health "in general" on a scale ranging from "excellent" to "poor". 
KEY POINTS
• The study examined recent trends in use and long-term use of prescription opioids in the USA.
• The prevalence of prescription opioid use increased from 4.1% of US adults in 1999-2000 to 6.8% in 2013-2014.
• The prevalence of long-term use of prescription opioids increased from 1.8% of US adults in 1999-2000 to 5.4% in 2013-2014.
• The increase in prevalence of long-term use explained the increasing trend in prescription opioid use overall.
• Long-term use of prescription opioids is associated with other correlates of adverse outcomes including poor health, concurrent benzodiazepine use, and history of heroin use.
Heroin use was ascertained in NHANES 2005-2014 by questions in the drug module of the survey. Participants were asked if they had ever used heroin and, among those who reported any lifetime heroin use, the timing of the last use.
Other variables in the analyses included sex, age, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other), and health insurance (private, Medicaid, Medicare, other types of insurance including VA, and no insurance).
| Statistical analyses
Analyses were conducted in 3 stages. In the first stage, the association of socio-demographic and clinical characteristics of the participants, as well as indicators of high risk use (ie, chronic physical health conditions, painful disability, concomitant use of benzodiazepines, alcohol use, and heroin use history) with any use and long-term use of prescription opioids were assessed using logistic regression models.
Next, temporal trends in any use and long-term use of prescription opioids over the 1999-2014 period were assessed. Binary logistic regression models were used for these analyses. Three separate models were run for overall use, long-term use, and short-term use.
The independent variable in these models was the survey wave, converted to a range between 0 (NHANES 1999-2000) and 1 (NHANES 2013-2014). Thus, odds ratios associated with these trends reflect change in odds of prescription opioid use over the whole 1999 to 2014 period. 32 Furthermore, incidence of new opioid use was estimated using the methodology previously described. 3 | RESULTS
| Correlates of prescription opioid use
A total of 2486 participants (5.5% of the 47 356 adult participants across the survey years) reported using prescription opioids in the past 30 days. In unadjusted logistic regression analyses, opioid use was more common in participants 25 years old or older compared to those less than 25 years, women compared to men, participants with public and "other" types of insurance compared to private insurance, participants with painful disabling conditions compared to those without such conditions, those with a larger number of chronic health conditions and poorer self-assessed health, participant with a greater number of health care visits, and those with overnight hospitalizations compared to those without such hospitalizations (Table 1) . Furthermore, the use of prescription opioid medications was associated with the concurrent use of prescription benzodiazepines and a history of heroin use. By contrast, prescription opioid use was less common in racial/ethnic minorities than in non-Hispanic whites and in those who used alcohol excessively ( Table 1) . were limited to these 2464 participants. In unadjusted analyses, longterm use was more common in older than younger adults, in those with public and the "other" kinds of insurance compared to private insurance, participants with a painful disabling condition, those with a larger number of chronic health conditions or a poorer self-assessed rating of health, and participants with a larger number of healthcare visits (Table 2 ). Long-term use was also more common among participant who currently used benzodiazepines or had a lifetime history of heroin use. However, Hispanics had lower odds of using opioids on a longterm basis compared to non-Hispanic whites, as did individuals who used alcohol excessively compared to those who did not use alcohol or used it moderately ( Table 2 ).
The associations with older age, Hispanic ethnicity, public insurance, painful disabling conditions, the number of chronic conditions, health status, and the use of benzodiazepines persisted in multivariable analysis. Individuals with past year hospitalization were less likely to be long-term users of benzodiazepines in multivariable analyses.
| Comparison of types of medications and health complaints
Long-term prescription opioid use was significantly more common in those who used tramadol, opium, morphine, fentanyl, and oxymorphone; whereas, long-term use was less common in those using codeine or meperidine (Appendix A). Long-term use was also more common among those who used more than 1 prescription opioid (odds ratio 
| Time trends
The prevalence of prescription opioid medication use increased from period remained statistically significant after adjusting for age, sex, Includes disability due to "arthritis/rheumatism", "back or neck problem", and "fractures, bone/joint injury".
b Includes history of arthritis, diabetes, thyroid problems, hypertension, hypercholesterolemia, angina, coronary arterial disease, heart attack, stroke, asthma, bronchitis, emphysema, hepatic disease, and cancer. Includes disability due to "arthritis/rheumatism", "back or neck problem", and "fractures, bone/joint injury".
b Includes history of arthritis, diabetes, thyroid problems, hypertension, hypercholesterolemia, angina, coronary arterial disease, heart attack, stroke, asthma, bronchitis, emphysema, hepatic disease, and cancer. 
| Sensitivity analyses
In sensitivity analyses, the temporal trends for prescription opioid use ≥30 days and <30 days were similar to those for use ≥90 days and <90 days, respectively (Appendix C). Furthermore, limiting the sample to medications for which the package was inspected did not substantively change the results (Appendix C).
| DISCUSSION
The results of this study are consistent with previous studies which indicated a growing trend in prescriptions and use of opioids over the past 2 decades. [1] [2] [3] 5, 9 Furthermore, the study found that the increasing trend in recent years was mainly due to a sharp increase in long-term use of these medications.
The trend in long-term use of prescription opioids is concerning because there is limited research evidence regarding the benefits of this form of opioid treatment and characteristics of individuals who would most benefit from this treatment. 33 A 2014 report by the Agency for Healthcare
Research and Quality failed to identify any randomized controlled trials assessing the efficacy of long-term prescription opioid use for pain. 34 However, the report found suggestive evidence of "increased risk of serious harms" associated with this pattern of prescription opioid use.
In the present study, the long-term use of prescription opioids was significantly more common among vulnerable groups at increased risk of developing opioid use disorder and other adverse health effects, such as individuals concurrently using benzodiazepines and those with a lifetime history of heroin use. 13, 17, 27, 29 Although only a small proportion of individuals using prescription opioids later develop an opioid use disorder, the increased prevalence of long-term use is a risk factor for this adverse outcome. 33, 34 Concomitant use of benzodiazepines with prescription opioids appears to be a growing trend 35 and is associated with a significant increase in the risk of overdose, even at moderate opioid doses. 36 Many patients who use benzodiazepines along with opioid medications receive these prescriptions from different clinicians, 37 highlighting the need for care-coordination and monitoring. 38 While the trends in long-term use of prescription opioids are clear and consistent with past research, the reasons for this trend are not well understood. There is little evidence that the trend is driven by an increase in the prevalence of chronic pain. 3, 9 The trend may reflect a change in practice style of physicians who may have become more attentive to complaints of pain and may have lowered the threshold for prescribing opioids for management of pain. 3 Concerns about poor management of pain in the past, "pain as the fifth vital sign" campaign, and direct to consumer advertising of pharmaceuticals may have also contributed to the change in physician practice styles and perhaps increased patient demands for opioid medications. 
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